In contrast, TREM2 is predicted to be a negative regulator of the ribosome, RNA binding, snRNA, and other metabolic processes in CESC, STAD, KIRP, ovarian serous cystadenocarcinoma (OV), READ, and SKCM (Figure 13A). This evidence concerns the gene TREM2 and ovarian serous cystadenocarcinoma.